Drugs for Neglected Diseases Initiative North America
Non-profit product development partnership
Based in NY
AI Overview
With $160K in lobbying spend across 17 quarterly filings, Drugs for Neglected Diseases Initiative North America is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2022 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2022 | $40K |
| 2023 | $40K |
| 2024 | $40K |
| 2025 | $40K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Drugs for Neglected Diseases Initiative North America disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Budget/Appropriations, MED
Issues related to neglected diseases research and development and access; COVID treatments research and development
Issues related to neglected diseases research and development and access; COVID treatments research and development; S. 3799 - PREVENT Pandemics Act.
FY 2022 and FY 2023 Labor, Health and Human Services, Education, and State and Foreign Operations funding for global health research and development and neglected tropical diseases and covid treatment
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.